SCGB 3A2Alternative Names: CG1011; Recombinant human secretoglobin 3A2; SCGB3A2
Latest Information Update: 19 May 2015
At a glance
- Originator Clarassance
- Developer Therabron Therapeutics
- Class Recombinant proteins
- Mechanism of Action Protein replacements
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Bronchiectasis; Pulmonary fibrosis